Literature DB >> 16916940

Differential utilization of cyclin D1 and cyclin D3 in the distinct mitogenic stimulations by growth factors and TSH of human thyrocytes in primary culture.

Sabine Paternot1, Jacques E Dumont, Pierre P Roger.   

Abstract

Two distinct mitogenic modes coexist in thyroid epithelial cells. TSH via cAMP induces proliferation and differentiation expression, whereas growth factors including epidermal growth factor (EGF) induce proliferation and dedifferentiation. Divergent models of TSH/cAMP-dependent mitogenesis have emerged from different thyroid cell culture systems. In the FRTL-5 rat cell line, cAMP cross-signals with transduction pathways of growth factors to induce cyclin D1 and p21(cip1) and down-regulate p27(kip1). By contrast, in canine primary cultures, mitogenic pathways of cAMP and growth factors are fully distinct. cAMP does not induce D-type cyclins and p21, it up-regulates p27, and it stimulates the formation and activity of cyclin D3-cyclin-dependent kinase (CDK) 4 complexes. In primary cultures of normal human thyrocytes, EGF + serum increased cyclin D1 and p21 accumulation, and it stimulated the assembly and activity of cyclin D1-CDK4-p21 complexes. By contrast, TSH repressed or did not induce cyclin D1 and p21, and it rather up-regulated p27. TSH did not increase cyclin D1-CDK4 activity, but it stimulated the activating phosphorylation of CDK4 and the pRb-kinase activity of preexisting cyclin D3-CDK4 complexes. As recently demonstrated in dog thyrocytes and other systems, cyclin D1 and cyclin D3 differently oriented the site specificity of CDK4 pRb-kinase activity, which might differently impact some pRb functions. Cyclin D1 or cyclin D3 are thus differentially used in the distinct mitogenic stimulations by growth factors or TSH, and potentially in hyperproliferative diseases generated by the overactivation of their respective signaling pathways. At variance with dog thyroid primary cultures, rat thyroid cell lines might not be valid models of TSH-dependent mitogenesis of human thyrocytes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16916940     DOI: 10.1210/me.2005-0515

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  11 in total

1.  Cyclic AMP inhibits the proliferation of thyroid carcinoma cell lines through regulation of CDK4 phosphorylation.

Authors:  Ana Sofia Rocha; Sabine Paternot; Katia Coulonval; Jacques E Dumont; Paula Soares; Pierre P Roger
Journal:  Mol Biol Cell       Date:  2008-09-17       Impact factor: 4.138

2.  Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.

Authors:  Roberta Malaguarnera; Kuen-Yuan Chen; Tae-Yong Kim; Jose M Dominguez; Francesca Voza; Bin Ouyang; Sushil K Vundavalli; Jeffrey A Knauf; James A Fagin
Journal:  J Clin Endocrinol Metab       Date:  2014-07-16       Impact factor: 5.958

3.  cAMP-dependent activation of mammalian target of rapamycin (mTOR) in thyroid cells. Implication in mitogenesis and activation of CDK4.

Authors:  Sara Blancquaert; Lifu Wang; Sabine Paternot; Katia Coulonval; Jacques E Dumont; Thurl E Harris; Pierre P Roger
Journal:  Mol Endocrinol       Date:  2010-05-19

4.  PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer.

Authors:  Kristen Wong; Francesca Di Cristofano; Michela Ranieri; Daniela De Martino; Antonio Di Cristofano
Journal:  Endocr Relat Cancer       Date:  2019-01-01       Impact factor: 5.678

5.  PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma.

Authors:  Valerie Cortez; Cathy Samayoa; Andrea Zamora; Lizatte Martinez; Rajeshwar R Tekmal; Ratna K Vadlamudi
Journal:  Cancer Res       Date:  2014-11-06       Impact factor: 12.701

6.  Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1.

Authors:  Binoj C Nair; Sujit S Nair; Dimple Chakravarty; Rambabu Challa; Bramanandam Manavathi; P Renee Yew; Rakesh Kumar; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  Cancer Res       Date:  2010-08-31       Impact factor: 12.701

7.  Differential regulation of cyclin-dependent kinase 4 (CDK4) and CDK6, evidence that CDK4 might not be activated by CDK7, and design of a CDK6 activating mutation.

Authors:  Laurence Bockstaele; Xavier Bisteau; Sabine Paternot; Pierre P Roger
Journal:  Mol Cell Biol       Date:  2009-06-01       Impact factor: 4.272

8.  Regulation of CDK4.

Authors:  Laurence Bockstaele; Katia Coulonval; Hugues Kooken; Sabine Paternot; Pierre P Roger
Journal:  Cell Div       Date:  2006-11-08       Impact factor: 5.130

9.  CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point.

Authors:  Xavier Bisteau; Sabine Paternot; Bianca Colleoni; Karin Ecker; Katia Coulonval; Philippe De Groote; Wim Declercq; Ludger Hengst; Pierre P Roger
Journal:  PLoS Genet       Date:  2013-05-30       Impact factor: 5.917

10.  Commentary: Thyrotropin Stimulates Differentiation Not Proliferation of Normal Human Thyrocytes in Culture.

Authors:  Aglaia Kyrilli; Sabine Paternot; Françoise Miot; Bernard Corvilain; Gilbert Vassart; Pierre P Roger; Jacques E Dumont
Journal:  Front Endocrinol (Lausanne)       Date:  2017-08-25       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.